Population pharmacokinetics of lamotrigine in Chinese children with epilepsy

被引:21
作者
He, Da-ke [1 ,2 ]
Wang, Li [1 ]
Lu, Wei [3 ]
Qin, Jiong [1 ]
Zhang, Shen [4 ]
Li, Ling [2 ]
Zhang, Jian-ming [2 ]
Bao, Wei-qun [2 ]
Song, Xiao-qing [2 ]
Liu, Hai-tao [5 ]
机构
[1] Peking Univ, Hosp 1, Dept Pediat, Beijing 100034, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat, Shanghai 200092, Peoples R China
[3] Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
[4] Beijing Childrens Hosp, Dept Neurol, Beijing 100045, Peoples R China
[5] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pharm, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
lamotrigine; Chinese children; population pharmacokinetics; NONMEM; epilepsy; ANTIEPILEPTIC DRUGS; CLINICAL PHARMACOKINETICS; CONCENTRATION-TOXICITY; VALPROATE; MONOTHERAPY; EFFICACY; THERAPY; ADULTS; NONMEM; MODEL;
D O I
10.1038/aps.2012.118
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: To establish a population pharmacokinetics (PPK) model for lamotrigine (LTG) in Chinese children with epilepsy in order to formulate an individualized dosage guideline. Methods: LTG steady-state plasma concentration data from therapeutic drug monitoring (TDM) were collected retrospectively from 284 patients, with a total of 404 plasma drug concentrations. LTG concentrations were determined using a HPLC method. The patients were divided into 2 groups: PPK model group (n=116) and PPK valid group (n=168). A PPK model of LTG was established with NONMEM based on the data from PPK model group according to a one-compartment model with first order absorption and elimination. To validate the basic and final model, the plasma drug concentrations of the patients in PPK model group and PPK valid group were predicted by the two models. Results: The final regression model for LTG was as follows: CL (L/h)=1.01(star)(TBW/27.87)(0.635 star)e(-0.753 star VPA star)e(0.868 star CBZ star)e(0.633 star PB), Vd (L)= 16.7(star)(TBW/27.87). The final PPK model was demonstrated to be stable and effective in the prediction of serum LTG concentrations by an internal and external approach validation. Conclusion: A PPK model of LTG in Chinese children with epilepsy was successfully established with NONMEM. LTG concentrations can be predicted accurately by this model. The model may be very useful for establishing initial LTG dosage guidelines.
引用
收藏
页码:1417 / 1423
页数:7
相关论文
共 50 条
[31]   Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy [J].
Inoue, Kazuyuki ;
Yamamoto, Yoshiaki ;
Suzuki, Eri ;
Takahashi, Toshiki ;
Umemura, Akiko ;
Takahashi, Yukitoshi ;
Imai, Katsumi ;
Inoue, Yushi ;
Hirai, Keita ;
Tsuji, Daiki ;
Itoh, Kunihiko .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (05) :555-562
[32]   Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy [J].
Biton, Victor .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (06) :1009-1018
[33]   Lamotrigine Serum Concentration in Children With Epilepsy [J].
Heyman, Eli ;
Lavie, Revital ;
Lahat, Eli ;
Braunstein, Rony ;
Bar-Haim, Adina ;
Berkovitch, Matitiahu ;
Gandelman-Marton, Revital .
PEDIATRIC NEUROLOGY, 2012, 47 (06) :427-430
[34]   Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling [J].
Shansen Xu ;
Limin Liu ;
Yanan Chen ;
Mei Liu ;
Tong Lu ;
Huanxin Wang ;
Shihao Liu ;
Mingming Zhao ;
Limei Zhao .
European Journal of Clinical Pharmacology, 2018, 74 :583-591
[35]   Population pharmacokinetics of lamotrigine in Indian epileptic patients [J].
Mallaysamy, Surulivelrajan ;
Johnson, Martin G. ;
Rao, Padma G. M. ;
Rajakannan, Thiyagu ;
Bathala, Lokesh ;
Arumugam, Karthik ;
van Hasselt, Johan G. C. ;
Ramakrishna, Devarakonda .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (01) :43-52
[36]   Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis [J].
Milovanovic, J. R. ;
Jankovic, S. M. .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (07) :428-436
[37]   PHARMACOKINETICS AND SAFETY OF LAMOTRIGINE (LAMICTAL) IN PATIENTS WITH EPILEPSY [J].
RAMSAY, RE ;
PELLOCK, JM ;
GARNETT, WR ;
SANCHEZ, RM ;
VALAKAS, AM ;
WARGIN, WA ;
LAI, AA ;
HUBBELL, J ;
CHERN, WH ;
ALLSUP, T ;
OTTO, V .
EPILEPSY RESEARCH, 1991, 10 (2-3) :191-200
[38]   Optimizing epilepsy therapy in children and adolescents with lamotrigine [J].
Siemes, H ;
Brandl, U ;
Helmstädter, C ;
Kurlemann, G ;
Rating, D ;
Sälke-Kellermann, RA ;
Stephani, U ;
Überall, M ;
Wiemer-Kruel, A ;
Bergmann, L .
KLINISCHE PADIATRIE, 2005, 217 (04) :222-229
[39]   Lamotrigine in children with refractory epilepsy [J].
Celebi, Asli ;
Yalnizoglu, Dilek ;
Turanli, Guezide ;
Topaloglu, Haluk ;
Aysun, Sabiha ;
Topcu, Meral .
TURKISH JOURNAL OF PEDIATRICS, 2008, 50 (05) :426-431
[40]   Characterization of lamotrigine disposition changes during and after pregnancy in women with epilepsy [J].
Karanam, Ashwin ;
Pennell, Page B. ;
Meador, Kimford J. ;
Long, Yuhan ;
Birnbaum, Angela K. .
PHARMACOTHERAPY, 2025, 45 (01) :33-42